Delaware
|
94-3023969
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
Incorporation)
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Exhibit No.
|
Description
|
|
99.1
|
Press
Release, dated December 1, 2010
|
|
99.2
|
Information
Sheet, dated December 1, 2010
|
|
99.3
|
Newsletter,
dated December
2010
|
PDL
BIOPHARMA, INC.
|
|
(Company)
|
|
By:
|
/s/ Christine R. Larson
|
Christine
R. Larson
|
|
Vice
President and Chief Financial
Officer
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated December 1,
2010
|
|
99.2
|
Information
Sheet, dated December 1, 2010
|
|
99.3
|
Newsletter,
dated December
2010
|